Press Room

2007 Press Releases

TSX:V - IXS
NASD OTC:BB: IXSBF

September 21, 2007

InNexus Biotechnology Hosts Open House and On-Site Technology Demonstration

British Columbia, Canada - September 18, 2007 - InNexus Biotechnology Inc. (OTCBB: IXSBF, TSX: IXS.V), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, announces today that it will host an open house and scientific technology demonstration at its state-of-the-art research and development facilities located on the campus of Mayo Clinic in Scottsdale, AZ on September 28, 2007 from Noon to 4:00pm.

Visitors to InNexus will come to 13208 East Shea Blvd., Suite 200 in the Mayo Clinic Collaborative Research Building for facility tours and an opportunity to meet with InNexus’ scientific team working on the Company’s recently announced cancer fighting product, DXL625 (CD20).

In addition to the open house, InNexus is also sponsoring a Scientific Technology Fair with the following companies staffing on-site demonstrations of their latest technologies. The scientific vendors will be on hand from Noon until 2:00pm and some of the companies included are Advanced Microarray, Applied BioSystems, Applied Microarray, Bio-Rad, Biotage, Fermentas, GE Healthcare, Laboratory Equipment Company, Molecular Devices, Rainin, Panomics and Zeiss. Researchers, media and interested shareholders are welcome and hungry visitors will be treated to snacks and beverages.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.

Contact

InNexus Biotechnology Inc.
Dr. Thomas Kindt, Chief Scientific Officer
480-862-7500

The Investor Relations Group
Investor Relations:
Christine Berni/Joe Triunfo, 212-825-3210
cberni@investorrelationsgroup.com
jtriunfo@investorrelationsgroup.com